C-reactive protein and depressed mood in a sub-group of smokers during nicotine abstinence

Human Psychopharmacology

Volumn 18, Issue 5, 2003, Pages 329-337

  Corwin, Elizabeth J ^a   Klein, Laura Cousino ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

C reactive protein; Depression; Interleukin; Mood; Nicotine abstinence; Smoking; Smoking cessation

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; NICOTINE;

ADULT; ANOREXIA; ANXIETY; ARTICLE; AUTOIMMUNE DISEASE; BRADYCARDIA; CARDIOVASCULAR FUNCTION; CIGARETTE SMOKING; CONTROLLED STUDY; DEPRESSION; FATIGUE; FEMALE; HEART RATE; HUMAN; HUNGER; HYPOTENSION; HYPOTHESIS; IMMUNE STATUS; INFECTION; INFLAMMATION; IRRITABILITY; MALE; MYALGIA; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RESTLESSNESS; SMOKING CESSATION; SYMPTOM; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; TOBACCO DEPENDENCE;

ADOLESCENT; BLOOD PRESSURE; C-REACTIVE PROTEIN; DEPRESSION; FEMALE; HEART RATE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; MALE; NICOTINE; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0041811682     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.487     Document Type: Article

References (67)

1. Al'absi M, Amunrud T, Wittmers LE. 2002. Psychophysiological effects of nicotine abstinence and behavioral challenges in habitual smokers. Pharmacol Biochem Behav 72: 707-716.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.
3. Anisman H, Merali Z. 1999. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 461: 199-234.
4. Bataille R, Klein B. 1992. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 35: 982-984.
5. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. 2002. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 89: 1117-1119.
6. Borrelli B, Niaura R, Keuthen NJ, Goldstein MG, DePue JD, Murphy C. 1996. Development of major depressive disorder during smoking cessation. J Clin Psychiatry 57: 534-538.
7. Center for Disease Control. 1998. Incidence of initiation of cigarette smoking-United States, 1965-1996. MMWR CDC Surveill Summ 47: 922-926.
8. Corwin EJ, Cannon JG. 1999. A physiological influence of fatigue in breastfeeding women. J Gend Specif Med 2: 30-34.
9. Corwin EJ, Klein LC, Rickelman K. 2002. Predictors of fatigue in healthy young adults: Moderating effects of cigarette smoking and gender. Biol Res Nurs 3: 222-233.
10. Covey LS, Glassman AH, Stetner F. 1997. Major depression following smoking cessation. Am J Psychiatry 154: 263-265.
11. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. 1999. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 20: 954-959.
12. Dantzer R, Aubert A, Bluthe RM, et al. 1999. Mechanisms of the behavioural effects of cytokines. Adv Exp Med Biol 461: 83-105.
13. Darko DF, Mitler MM, Henriksen SJ. 1995. Lentiviral infection, immune response, peptides, and sleep. Adv Neuroimmunol 5: 57-77.
14. Dinarello CA. 1996. Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
15. Dinarello CA. 1999. Cytokines as endogenous pyrogens. J Infect Dis 179(Suppl. 2): S294-S304.
16. Dobbin JP, Harth M, McCain GA, Martin RA, Cousin K. 1991. Cytokine production and lymphocyte transformation during stress. Brain Behav Immun 4: 339-348.
17. Escobedo LG, Reddy M, Giovino GA. 1998. Relationship between depressive symptoms and cigarette smoking in US adolescents. Addiction 93: 433-440.
18. Ferrence R, Slade J, Room R, Pope M (eds). 2000. Nicotine and Public Health. American Public Health Association: Washington, DC.
19. Francus T, Romano PM, Manzo G, Fonacier L, Arango N, Szabo P. 1992. IL-1, IL-6, and PDGF mRNA expression in alveolar cells following stimulation with a tobacco-derived antigen. Cell Immunol 145: 156-174.
20. Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454.
21. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. 1987. Interferon b2/B-cell stimulatory factor type 2 shares identify with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84: 7251-7255.
22. Glassman AH, Covey LS, Stetner F, Rivelli S. 2001. Smoking cessation and the course of major depression: A follow-up study. Lancet 357: 1929-1932.
23. Gonzales D, Bjornson W, Durcan MJ, et al. 2002. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prevent Med 22: 234-239.
24. Hagiwara E, Takahashi KI, Okubo T, et al. 2001. Cigarette smoking depletes cells spontaneously secreting Th(1) cytokines in the human airway. Cytokine 14: 121-126.
25. Hart BL. 1988. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12: 123-137.
26. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. 1991. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Addiction 86: 1119-1127.
27. Hockertz S, Emmendorffer A, Scherer G, et al. 1994. Acute effects of smoking and high experimental exposure to environmental tobacco smoke (ETS) on the immune system. Cell Biol Toxicol 10: 177-190.
28. Hughes JR. 1999. Comorbidity and smoking. Nicotine Tob Res 1(Suppl. 2): S149-S152.
29. Hughes JR, Higgins ST, Bickel WK. 1994. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89: 1461-1470.
30. Jorenby D. 2002. Clinical efficacy of bupropion in the management of smoking cessation. Drugs 62(Suppl. 2): 25-35.
31. Kent S, Bluthe R, Kelley K, Dantzer R. 1992. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 13: 24-28.
32. Kent S, Bret-Dibat JL, Kelley KW, Dantzer R. 1996. Mechanism of sickness-induced decreases in food-motivated behavior. Neurosci Biobehav Rev 20: 171-175.
33. Kinnunen T, Doherty, Militello FS, Garvey AJ. 1996. Depression and smoking cessation: characteristics of depressed smokers and effects of nicotine replacement. J Consult Clin Psychol 64: 791-798.
34. Klein LC, Corwin EJ, Stine MM. Smoking abstinence impairs time estimation accuracy in cigarette smokers. Psychopharmacology Bull 37: (in press).
35. Koenig W, Sund M, Frohlich M, et al. 1999. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99: 237-242.
36. Kop WJ, Gottdiener JS, Tangen CM, et al. 2002. Inflammation and coagulation factors in persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 89: 419-424.
37. Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. 1994. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HIS. Drug Alcohol Depend 34: 211-216.
38. Licinio J, Wong M-L. 1999. Role of inflammatory mediators in the biology of major depression: CNS cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 4: 317-327.
39. Maier SF, Watkins LR. 1998. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 105: 83-107.
40. Meliska CJ, Stunkard ME, Gilbert DG, Jensen RA, Martinko JM. 1995. Immune function in cigarette smokers who quit smoking for 31 days. J Allergy Clin Immunol 95: 901-910.
41. Mendall MA, Strachan DP, Butland BK, et al. 2000. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 21: 1584-1590.
42. Morley JJ, Kushner I. 1982. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 389: 406-418.
43. O'Hara P, Portser SA, Anderson BP. 1989. The influence of menstrual cycle changes on the tobacco withdrawal syndrome in women. Addict Behav 14: 595-600.
44. Ohta T, Yamashita N, Maruyama M, Sugiyama E, Kobayashi M. 1998. Cigarette smoking decreases interleukin-8 secretion by human alveolar macrophages. Respir Med 92: 922-927.
45. Parrott AC, Garnham NJ, Wesnes K, Pincock C. 1996. Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. Human Psychopharmacol 11: 391-400.
46. Perkins KA, Donny E, Caggiula AR. 1999. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob Res 1: 301-315.
47. Perkins KA, Levine M, Marcus M, et al. 2000. Tobacco withdrawal in women and menstrual cycle phase. J Consult Clin Psychol 68: 176-180.
48. Radloff LS. 1977. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure 1: 385-401.
49. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. 1997. Inflammation, aspirin, and the risk of cardiovascular discase in apparently healthy men. N Engl J Med 336: 973-979.
50. Ridker PM, Hennekens CH, Buring JE, Rifai N. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
51. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
52. Rigotti NA. 2002. Clinical practice: treatment of tobacco use and dependence (review). N Engl J Med 346: 506-512.
53. Rothermundt M, Arolt V, Peters M, et al. 2001. Inflammatory markers in major depression and melancholia. J Affect Disord 63: 93-102.
54. Royal College of Physicians. 2000. Nicotine Addiction in Britain. Lavenham Press: Sudbury, Suffolk.
55. Schneider NG, Jacob P, Nilsson F, Leischow SJ, Benowitz NL, Olmstead RE. 1997. Saliva cotinine levels as a function of collection method. Addiction 92: 347-351.
56. Schneider RA. 1998. Concurrent validity of the Beck depression inventory and the multidimensional fatigue inventory-20 in assessing fatigue among cancer patients. Psychol Rep 82: 883-886.
57. Silverman NA, Potvin C, Alexander JC, Jr, Chretien PB. 1975. In vitro lymphocyte reactivity and T-cell levels in chronic cigarette smokers. Clin Exp Immunol 22: 285-292.
58. Smets EMA, Garssen B, Bonke B, De Haes JCJM. 1995. The multi-dimensional fatigue iliventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39: 315-325.
59. Soliman DM, Twigg HL, III. 1992. Cigarette smoking decreases bioactive interleukin-6 secretion by alveolar macrophages. Am J Physiol 263(4 Pt. 1): L471-L478.
60. Song C, Dinan T, Leonard BE. 1994. Changes in immunoglobulin complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 30: 283-288.
61. Sonti G, Ilyin SE, Plata-Salaman CR. 1996. Anorexia induced by cytokine interactions at pathophysiology concentrations. Am J Physiol 270(6 Pt. 2): R1394-R1402.
62. Spielberger CD. 1983. State-Trait Anxiety Inventory: A Comprehensive Bibliography. Consulting Psychologists Press: Palo Alto, CA.
63. Torrens PR, Lynch BS, Bonnie RJ. 1995. From the Institute of Medicine. JAMA 273: 1326.
64. Tracy RP, Psaty BM, Macy E, et al. 1997. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and sub-clinical disease in healthy elderly Subjects. Arterioscler Thromb Vasc Biol 17: 2167-2176.
65. U.S. Department of Health and Human Services. 1994. Preventing Tobacco Use among Young People: A Report of the Surgeon General. U.S. Government Printing Office: Washington, DC.
66. Wallenfeldt K, Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. 2001. Carotid and femoral atherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year-old men. J Intern Med 250: 492-501.
67. West RJ, Hajek P, Belcher M. 1989. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 19: 981-985.